Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 12/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16024774 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL16140840 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL15588638 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL16140841 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL16153685 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL15721493 | 1.00 | BTN3A1 (0.54) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL16015987 | 0.94 | BTN3A1 (0.58) | BTN3A1MEN1KMT2ANPSR1CYP3A4 | |
| SCHEMBL13660267 | 0.90 | BTN3A1 (0.53) | BTN3A1MEN1KMT2ANPSR1KDM4E | |
| SCHEMBL16576300 | 0.90 | BTN3A1 (0.53) | BTN3A1MEN1KMT2ANPSR1KDM4E | |
| SCHEMBL25709714 | 0.90 | BTN3A1 (0.53) | BTN3A1MEN1KMT2ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9216960-B2 | Spiro[2.4]heptanes for treatment of Flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-8946242-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8921384-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2801580-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2792680-A1 | Nucleoside phosphoramidate prodrugs | Gilead Pharmasset LLC (US) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014165542-A1 | 2',4'-FLUORO NUCLEOSIDES FOR THE TREATMENT OF HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140140957-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140958-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8673926-B2 | Spiro[2.4]heptanes for treatment of flaviviridae infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130224152-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140958-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | BTN3A1 4223/4885MEN1 4320/4885KMT2A 4122/4885 |
| US-20130224152-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | BTN3A1 4223/4885MEN1 4320/4885KMT2A 4122/4885 |
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, TYMP | BTN3A1 3530/4885MEN1 3685/4885KMT2A 3595/4885 |
| US-20140140957-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | BTN3A1 4223/4885MEN1 4320/4885KMT2A 4122/4885 |
| US-20150079036-A1 | Spiro[2.4]heptanes for Treatment of Flaviviridae Infections | HAVCR2, SLC10A1, CYP8B1 | BTN3A1 4223/4885MEN1 4320/4885KMT2A 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.